<DOC>
	<DOCNO>NCT00112554</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cytarabine VNP40101M , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This randomized phase III trial study cytarabine VNP40101M see well work compare cytarabine alone treat patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Cytarabine With Without VNP40101M Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare complete response ( CR ) CR ( platelet count &lt; 100,000/mm^3 ≥ 20,000/mm^3 [ transfusion independent ≥ 7 consecutive day ] ) ( CRp ) rate patient acute myeloid leukemia first relapse treat cytarabine v without VNP40101M . Secondary - Compare time progression patient treat regimen . - Compare duration response patient treat regimen . - Compare survival patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , double-blind , placebo-controlled , parallel group , multicenter study . Patients stratify accord age ( &lt; 60 year vs ≥ 60 year ) duration first complete response ( CR ) CR ( platelet count &lt; 100,000/mm³ ≥ 20,000/mm³ [ transfusion independent ≥ 7 consecutive day ] ) ( CRp ) ( &lt; 12 month vs ≥ 12 month ) . - Induction therapy : Patients randomize 1 2 treatment arm . - Arm I : Patients receive cytarabine IV continuously day 1-3 VNP40101M IV 30-60 minute day 2 ( least 12 hour start cytarabine ) . - Arm II : Patients receive cytarabine arm I placebo IV 30-60 minute day 2 ( least 12 hour start cytarabine ) . In arm , patient demonstrate least 20 % reduction blast bone marrow ( base total cellularity percent blast ) course 1 may receive 1 additional course induction therapy day 35-60 absence disease progression unacceptable toxicity . Patients achieve CR CRp 1 2 course induction therapy proceed consolidation therapy . - Consolidation therapy : Beginning 6 week initial documentation CR CRp , patient receive 1 course consolidation therapy , per induction therapy , accord randomize treatment arm . These patient may proceed consolidation , maintenance , and/or intensification therapy ( include stem cell transplantation ) study discretion physician . After completion study treatment , patient follow monthly 6 month , every 2 month 6 month , every 3 month 2 year . PROJECTED ACCRUAL : A total 420 patient ( 280 arm I 140 arm II ) accrue study within 24-30 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia ( AML ) Any WHO classification , exclude acute promyelocytic leukemia At least 10 % blast bone marrow aspirate and/or biopsy In first relapse achieve first complete response ( CR ) OR CR ( platelet count &lt; 100,000/mm³ ≥ 20,000/mm³ [ transfusion independent ≥ 7 consecutive day ] ) ( CRp ) last ≥ 3 month ≤ 24 month completion initial induction regimen Relapse confirm recurrence blast peripheral blood , bone marrow histopathology , and/or histologically confirm CNS extramedullary disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 3 time ULN Chronic hepatitis allow Renal Creatinine ≤ 2.0 mg/dL Cardiovascular No myocardial infarction within past 3 month No uncontrolled arrhythmias No uncontrolled congestive heart failure Pulmonary No severe chronic obstructive pulmonary disease No requirement supplemental oxygen rest Immunologic No uncontrolled active infection Infections control active treatment antibiotic allow No evidence invasive fungal infection blood tissue culture Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No clinical evidence another active malignancy tumor marker , pathology , radiologic study No severe medical condition would preclude study treatment PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 12 hour since prior hydroxyurea Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior treatment first relapse except hydroxyurea No concurrent standard investigational treatment AML No concurrent disulfiram ( Antabuse® )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
</DOC>